<unk> , sold under the brand name Anthim, is a monoclonal antibody medication designed for the treatment of exposure to Bacillus anthracis spores (etiologic agent of anthrax). The medication was developed by Elusys Therapeutics, Inc.
Obiltoxaximab
Atoltivimab
Regdanvimab
Sotrovimab
Odesivimab
Nirsevimab
Bebtelovimab
Lirentelimab